502 abstracts found.



F-18 labelled 3’-deoxy-3’-fluorothymidine (FLT) positron emission tomography (PET) imaging in patients with advanced pancreatic ductal adenocarcinoma: proof-of-concept reproducibility sub-analysis.

Year:

Session type:

Theme:

Angela Lamarca1,Prakash Manoharan2,Marie-Claude Asselin3,Peter J Julyan4,Mahbubunnabi Tamal3,Ioannis Trigonis3,Mairéad G McNamara5,Richard A Hubner1,Zarni Win6,Juan W Valle5,Azeem Saleem7
1Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom,2Department of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom,3University of Manchester Wolfson Molecular Imaging Centre (WMIC), Institute of Population Health, Manchester, United Kingdom,4Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, United Kingdom,5Department of Medical Oncology, The Christie NHS Foundation Trust; Institute of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom,6Department of Radiology, Imperial College Healthcare NHS Trust, London, United Kingdom,7Department of Applications, Imanova Centre for Imaging Sciences, London, United Kingdom

THE PROMIS STUDY: DIAGNOSTIC ACCURACY OF MRI AND TRUS BIOPSY IN PROSTATE CANCER

Year:

Session type:

Theme:

Louise Brown1,Hashim Ahmed2,Ahmed El-Shater Bosaily2,Gabe Rhian3,Kaplan Richard1,Yolanda Collaco-Moraes1,Katie Ward1,Richard Hindley4,Alex Freeman5,Alex Kirkham5,Robert Oldroyd6,Chris Parker7,Mark Emberton2,The PROMIS Study Group8
1MRC Clinical Trials Unit at UCL,2University College London,3University of York,4Hampshire Hospitals NHS Foundation Trust,5University College London Hospital NHS Foundation Trust,6Patient and Public Representative,7Royal Marsden Hospital,8PROMIS Collaborators

Comprehensive analysis of cell-free tumour DNA in plasma and urine tracks disease burden and reveals clonal evolution in muscle invasive bladder cancer

Year:

Session type:

Theme:

Christopher Smith1,Kristan van der Vos2,Keval Patel1,Charles Massie1,Francesco Marass1,James Morris1,Dana Tsui1,Florent Mouliere1,Vincent Gnanapragasam1,Tim Forshew3,Bas van Rhijn2,Nitzan Rosenfeld1,Michiel van der Heijden2
1University of Cambridge,2Netherlands Cancer Institute,3University College London

Inhibiting HOX-PBX binding in paediatric glioblastoma as a novel therapeutic treatment

Year:

Session type:

Theme:

William Rogers1,Richard Morgan2,Hardev Pandha1
1University of Surrey,2University of Bradford

HPV drives tumor development throughout the head and neck: Improved prognosis is associated with an immune response largely restricted to the oropharynx

Year:

Session type:

Theme:

Tim Fenton1,Ankur Chakravarthy1,Stephen Henderson1,Stephen Thirdborough2,Christian Ottensmeier2,Xiaoping Su3,Andrew Feber1,Matt Lechner1,Gareth Thomas2
1University College London,2University of Southampton,3MD Anderson Cancer Center, University of Texas

PARP trapping enhances oncolytic Reovirus cell killing in melanoma

Year:

Session type:

Theme:

Joan Kyula-Currie1,Victoria Roulstone2,Richard Elliot3,Stephen Pettitt3,Dragomir Krastev3,Holly Barker3,Martin McLaughlin3,Chris Lord3,Alan Melcher3,Kevin Harrington3
1Instiitute of Cancer Research,2Institute of Cancer Research,3Institute of cancer research

Metformin increases 18F-FDG flux and inhibits fatty acid oxidation at clinical doses in breast cancer: results of a phase 0 clinical trial

Year:

Session type:

Theme:

Simon Lord1,Dan Liu1,Wei-Chen Cheng1,Syed Haider1,Edoardo Gaude2,Eugene Teoh1,Neel Patel1,Tom Metcalf3,Daniel McGowan1,Ioannis Roxanis1,Zhang Qifeng4,Pankaj Roy5,Fergus Gleeson1,Alastair Thompson6,Michael Pollak7,Michael Wakelam4,Francesca Buffa1,Christian Frezza2,John Fenwick3,Adrian Harris1
1University of Oxford,2University of Cambridge,3University of Liverpool,4Babraham Institute,5Oxford University Hospitals NHS Foundation Trust,6MD Andersen Cancer Centre,7McGill University

PET-PANC: Multi-centre trial of 18Fluorine-2-fluoro-2-deoxy-D-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.

Year:

Session type:

Theme:

Paula Ghaneh1,Wai-Lup Wong2,Sobhan Vinjamuri3,Colin Johnson4,Mohamed Abu Hilal5,Antony Higginson6,Andrew Smith7,Andrew Scarsbrook8,Colin Mckay9,Robert Sutcliffe10,Hemant Kocher11,David Cunningham12,Stephen Pereira13,Brian Davidson14,David Chang15,Saboor Khan16,Bal Sanghera17,Andrew Titman18,Gillian Lancaster19,Catrin Plumpton20,Seow Tien Yeo21,Robert Hanson22,Christopher Halloran23,John Neoptolemos23
1University of Liverpool,2Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK,3Royal Liverpool and Broadgreen University Hospitals NHS Trust,4Faculty of Medicine, University of Southampton, Southampton, UK.,5Department of Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK.,6Department of Radiology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.,7Department of Gastrointestinal Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK.,8Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.,9Department of Surgery, Glasgow Royal Infirmary - NHS Greater Glasgow and Clyde, Glasgow, UK.,10Department of Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.,11Barts Cancer Institute, Barts and the London, London, UK.,12Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London, UK.,13Institute for Liver and Digestive Health, University College London Hospitals NHS Foundation Trust, London, UK.,14Department of Surgery, Royal Free London NHS Foundation Trust, London, UK.,15Department of Surgery, Royal Blackburn Hospital- East Lancashire Hospitals NHS Trust, Blackburn,UK.,16Department of Surgery, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.,17Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK.,18Department of Mathematics and Statsistics, Lancaster University, Lancaster, UK,19Department of Mathematics and Statsistics, Lancaster University, Lancaster, UK.,20Centre for Health Economics and Medicines Evaluation, Bangor University, Lancaster, UK.,21Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK.,22Liverpool Cancer Research UK Cancer Trials Unit, University of Liverpool, Liverpool, UK,23Department Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.

Updated results from a phase 3 trial of nivolumab combined with ipilimumab in treatment-naive patients with advanced melanoma (CheckMate 067)

Year:

Session type:

Theme:

Jedd Wolchok1,Vanna Chiarion-Sileni2,Rene Gonzalez3,Piotr Rutkowski4,Jean-Jacques Grob5,C. Lance Cowey6,Christopher Lao7,Dirk Schadendorf8,Pier Ferrucci9,Michael Smylie10,Reinhard Dummer11,Andrew Hill12,John Haanen13,Michele Maio14,Grant McArthur15,Dana Walker16,Joel Jiang16,Christine Horak16,James Larkin17,F. Stephen Hodi18
1Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College,2Oncology Institute of Veneto IRCCS,3University of Colorado Cancer Center,4Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology,5Hospital de la Timone,6Texas Oncology-Baylor Charles A. Sammons Cancer Center,7University of Michigan,8Department of Dermatology, University of Essen,9European Institute of Oncology,10Cross Cancer Institute,11Universitäts Spital,12Tasman Oncology Research,13Netherlands Cancer Institute,14University Hospital of Siena,15Peter MacCallum Cancer Centre,16Bristol-Myers Squibb,17Royal Marsden Hospital,18Dana-Farber Cancer Institute

The molecular epidemiology of rare and compound EGFR mutations in 14,304 non-small cell lung carcinomas

Year:

Session type:

Theme:

Matthew Evans1,Brendan O'Sullivan1,Frances Hughes1,Claire Swift1,Reena Dessi1,Tina Mullis1,Matthew Smith1,Philippe Taniere1
1Queen Elizabeth Hospital Birmingham

Page 1 of 511...25...Last »